The Food And Drug Administration (FDA) is an important force in healthcare and the regulation of pharmaceuticals and this role has undoubtedly increased in importance in the recent past. With more companies producing drugs, for which the demand has gone up with the successful diagnosis of more ailments, it is important to keep on top of the market. As such, it may come as no surprise that the FDA has started to take action against individual companies that make drugs for making inaccurate or incomplete statements while advertising their pharmaceuticals.

In fact, in late December 2009 the FDA cited four different pharmaceutical companies for failing to inform medical facilities and the public in full about their products. Full disclosure was not found to be present in the promotion materials of Eli Lilly, Bayer, Cephalon, and Amylin Pharmaceuticals, and the marketing enforcement division has officially sent letters to each one citing the exact problems. All four have been cited for omitting or misrepresenting the risks associated with various medications or their side effects. These letters are nothing new because they are regularly issued to companies failing to comply with guidelines, but safety is now more important than ever given the wealth of pharmaceuticals available to treat different problems.

Withholding information from the public by pharmaceutical companies has long been a problem for the FDA and their enforcement division. The emphasis that has been placed on full disclosure is geared towards protecting the safety of individuals that may need to take the drugs and whose failure to do so can cause serious problems and, in the worst cases, could even lead to death. Everyone has the absolute right to know what they are taking and what the potential side effects are so the FDA’s action will hopefully reinforce that point and force companies to look after public help as far as possible.

http://www.msnbc.msn.com/id/34827064/ns/health-health_care/